Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Credit Suisse Investor Conference (March 2017)
20 slides from Aurobindo Pharma's conference presentation, March 2017
Slide 1: Leading Vertically Integrated Generic Player
LEADING VERTICALLY INTEGRATED GENERIC PLAYER Credit Suisse Investor Conference March 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any
Slide 3: Executive Summary
Executive Summary Among the Top-5 listed pharmaceutical companies from India by sales(1) 7th largest generic company by volume in the US; IMS TRx represents greater than 34% growth year over year (2) Broad portfolio of diversified dosage forms including Rx and OTC oral solids, liquids, injecta
Slide 4: Emerged into a leading global generic player
Emerged into a leading global generic player 2006 2016 Revenue US$ 244 million US$ 2.1 billion EBITDA margin (%) 11.1% 23.1% Formulations 16% 79% contribution US Formulations 3% 44% contribution EU Formulations 3% 22% contribution Manufacturing 7 facilities including 3 22 facilities including 11 fac
Slide 5: The Journey So Far…
The Journey So Far… 2013 Commenced marketing specialty injectables in USA Building capabilities in Penem and Oncology 2006-08 Acquired UK based Milpharm 2014 Acquired formulations facility Acquired Western European in US commercial operations from Investment in building Actavis manufactu
Slide 6: Core Strengths
Core Strengths Scale & Operational Customer Leadership Strengths Centricity • Large manufacturing • High vertical integration • Global marketing network facilities inspected by in over 150 countries leading regulatory bodies • Robust and highly scalable formulations • Customer centric approach • Wel
Slide 7: Diversified Revenue Base & Strong Organic growth
Diversified Revenue Base & Strong Organic growth Gross sales ~US$ 1.1 billion FY13 25% CAGR FY16 *major markets include Brazil, South Africa, Ukraine, and Mexico Gross sales US$ Mn 6
Slide 8: Financial Performance Trend
Financial Performance Trend Operating income (US$ Mn) EBITDA & PAT Margin (%) EPS (INR/Share) Gross Block & Fixed Asset Turnover Average ROE & ROCE % Net Debt/Eq & Net Debt/EBITDA Gross Block is calculated as Tangible Assets + Intangible Assets-Goodwill 7 *As per Indian Accounting Standards (Ind AS)
Slide 9: Our Business Segments
Our Business Segments US EU Ranked 7th* Rx supplier as per Among top 15** Gx companies IMS total prescriptions dispensed by sales Differentiated pipeline with new Focus markets are France, launches including injectables, Germany, Netherlands, Spain, ophthalmics, speciality products UK, Portu
Slide 10: US Business Overview
US Business Overview Aurobindo USA AuroMedics AuroLife Pharma AuroHealth Natrol Oral Rx Injectables Manufacturing / Pharma OTC Dietary Supplements R&D Addressable Cumulative ANDA Filings and Approvals 421 Therapy ANDAs Market Size 398 (US$ Bn) 376 118 Anti Diabetic 12 3.2 336 147 ARV 39 2.5 269 183
Slide 11: US: Expanding Portfolio Mix Towards Differentiated Products
US: Expanding Portfolio Mix Towards Differentiated Products Unit wise ANDA Filings as on 31-December-2016 Final Tentative Under Site Details Total Approval Approval Review Unit III Oral Formulations 99 16 10 125 Unit IV Injectables & Ophthalmics 38 2 35 75 Unit VIB Cephalosphorins Oral 11 11 Unit VI
Slide 12: Enhanced Research & Development Capabilities
Enhanced Research & Development Capabilities 5 R&D centers in Hyderabad, India Focus on building Focused on difficult to develop API, niche oral, sterile and specialty injectable differentiated product portfolio Concentrating on wide range of Oncology, Hormonal products, Penems, Enzymes, Biocata
Slide 13: EU Business Overview
EU Business Overview France Germany Netherlands Spain UK Portugal Italy Romania Belgium India’s Leading Gx company with strong footprint in Europe Gross Sales** 600 30 Operations in 9 countries with full fledged sales force & support 26 infrastructure 22 22 25 Significant presence and position
Slide 14: EU: Portfolio Mix Across Channels
EU: Portfolio Mix Across Channels Sales split by Channel Sales split by Therapeutic Profile Sales split by Dosage Forms Powder Gel 2% 1% Dermatology Others Cream 5% 10% CV & Liquid 1% Resp 13% Antineo plastic 27% 7% Injectables Digestive & Others Capsule Tablet 15% 10% 15% 58% Anti- CNS infective 22
Slide 15: ARV Business Overview
ARV Business Overview Focus on global tenders floated by Multi-Lateral Organizations like Gross Sales (US$ Mn) Global Fund, USAID/PEPFAR and Country specific MOH tenders; 250 15 currently caters to 2.2 million HIV+ patients 13 Well integrated supply chain management services and logistics for 15
Slide 16: Emerging Markets Business Overview
Emerging Markets Business Overview Canada Ukraine GCC Countries Myanmar Mexico Tanzania Colombia Brazil South Africa Growth markets Growth Drivers in the next 3-4 years Gross Sales (US$ Mn) 150 7 8 6 11% CAGR Build branded generics presence 5 5 5 6 100 4 Enhance penetration in selected markets t
Slide 17: The Base Business: API
The Base Business : API Strong Regulatory Capability* API business continue to focus on high value, specialty, small/mid- size products with a limited competition Ensures quality & reliability of supplies and ability to command cost efficiencies as well as economies of scale 404 Focus on conti
Slide 18: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (US$ Mn) Mar-15 Mar-16 Dec-16 690 748 529 Fx Loan restated 690 748 529 Rupee Loan 6 7 9 Sales Tax Deferment 9 6 0 Gross Debt 705 762 538 Cash Balance 72 122 129 Net Debt 633 640 410 Finance Cost 1.9% 1.8% 1.6% Fx Debt and Fx Cash Balance are reinstated 17
Slide 19: Initiatives to Support Sustainable Future Growth
Initiatives to Support Sustainable Future Growth Short Term Medium Term Long Term Focus on strengthening the Portfolio, Commercial Drivers: Focus on launches Focus on increasing and sustaining the Capability and Capacity as Growth Drivers Peptides number of filings and launches of high- Additional
Slide 20: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725000/5401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Register
Aurobindo Pharma — Credit Suisse Investor Conference (March 2017) on 6ix